Sure...
Short answer. There is no announced commercial agreement between NWBO and Zeon.
Nothing in NWBO’s SEC or MHRA filings or in Zeon’s releases says Zeon is or will be the contracted Eden supplier.
What does exists is a clean, verifiable lineage that makes Zeon an obvious technical fit for Eden-class cartridges. That is what “completed the physical supply chain” means. It is not a guarantee of supply.
Complete answer with lineage and fit:
1. Flaskworks to Eden to NWBO
2016 to 2020. Shashi Murthy’s team at Flaskworks patented a closed, low shear, dual chamber dendritic cell bioreactor with duty cycle pumps, gas barrier low extractables films, sterile welded tubing, and full sensorization. Examples include US 10,647,954 and US 12,071,606 and US 12,173,265. NWBO acquired Flaskworks outright in August 2020, so Eden is an NWBO owned platform. Eden’s consumables are single use polymer cartridges with molded micro features, anti adhesion coatings, gamma or E beam sterilization, and Annex 11 or Part 11 traceability.
2. GPB Scientific to Curate DCS upstream
2017 to 2024. GPB Scientific later Curate commercialized deterministic lateral displacement. Micropost arrays separate leukocytes from leukopaks without centrifugation. Amgen Ventures led a 25.5 million round in April 2020 and placed Philip Tagari on the board, which validated the platform for cell therapy manufacturing. Curate training material shows leukopak collection in ACD A citrate, additional citrate added, overnight 2 to 8 °C storage on a rocker, and cassette assembly. That is the same anticoagulated, cold chain, low shear upstream used to feed Eden with clean CD14 positive monocytes.
3. Zeon consolidates resin, molding, and DLD IP
December 2022. Zeon acquired Edge Precision Manufacturing in Massachusetts, an ISO 13485 micro molder for high tolerance microfluidics and diagnostics.Before that Zeon already owned ZEONEX and ZEONOR cyclo olefin polymers, which are low extractables, low autofluorescence, high gas barrier resins compatible with gamma and E beam sterilization and widely used for microfluidic cartridges.September 2025. Zeon announced it had acquired Curate or GPB’s DCS patent estate and is integrating the geometry into Edge toolsets for OEM supply. Public statements by Zeon’s CSO Alison Skelley referenced more than fifteen years of work with Edge on DLD class geometries.
Result. As of September 2025 a single tier one supplier controls the resin, the micro molding, and the DLD flow geometry that you would specify for single use COP Eden cartridges used for gentle immune cell enrichment and low shear perfusion.
4. Where this touches Eden’s bill of materials
Eden needs three things.
First, bulk polymer and optics. Gas tight, low extractables films and plates, clear windows for optical sensing, gamma or E beam proof, weldable. COP or COC is the industry standard.
Second, micro features and flow control. Molded microchannels, pillars, diffusers, and manifolds that hold shear below about 0.1 dyn cm², maintain residence time distribution, and present non adhesive surfaces such as PEG or Pluronic. Edge has the micro molding and the Curate DCS geometry is a proven deterministic pattern.
Third, upstream enrichment. Eden can accept CliniMACS, counter flow systems such as CTS Rotea, or deterministic sieving DCS cassettes. DCS is filterless, gentle, and cost efficient, and is suitable for point of care hub and spoke deployment under UK SI 2025 87.
5. UCLA and regulator context that reinforce the configuration
UCLA papers in Nature Biomedical Engineering 2024 and Nature Protocols 2025 specify COP or COC microchannels and low shear about 0.1 dyn cm² viscoelastic flow as the optimum for antigen presenting cells and T cell activation. That is effectively a materials and fluid specification that maps directly to COP microfluidic supply.UK SI 2025 87 creates the Control site Decentralised Manufacturing Master File at Advent. Supplier qualification, extractables and leachables, sterilization validation, incoming QC, and change control flow through the DMMF. If NWBO were to adopt Zeon or Edge COP or DCS parts, the governance path with MHRA already exists.
6. What is and is not public
There is no NWBO Zeon contract disclosed. Treat Zeon as a technically ideal candidate OEM or OES supplier, not a confirmed supplier. Possible procurement paths include direct OEM Zeon or Edge to NWBO or Flaskworks, an integrator route such as 3P innovation that sources COP parts from Zeon or Edge and completes GMP assembly, or a CDMO route such as Thermo Fisher or Patheon that places the Eden cartridge in the bill of materials and subcontracts COP or DCS inserts from Zeon or Edge. Alternatives exist such as TOPAS for COP and Micronit, Microfluidic ChipShop, IMT, Dolomite, or Axxicon for molding, and NWBO can dual source to manage risk.
7. Bottom line
Facts. Zeon owns DCS IP and Edge micro molding and supplies ZEONEX or ZEONOR COP. Eden requires COP or COC, micro featured, low shear, low extractables disposables. There is no disclosed NWBO Zeon supply agreement. Reasonable inference. Zeon’s consolidation of resin, tool making, and deterministic geometry lowers execution risk for any Eden class implementer that chooses COP microfluidics, including NWBO, but it is not a promise or guarantee of supply.
AI
Market Data 
Markets 
